TY - JOUR
T1 - A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma
AU - Hofmeister, Craig C.
AU - Williams, Nita
AU - Geyer, Susan
AU - Hade, Erinn M.
AU - Bowers, Mindy A.
AU - Earl, Christian T.
AU - Vaughn, John
AU - Bingman, Anissa
AU - Humphries, Kristina
AU - Lozanski, Gerard
AU - Baiocchi, Robert A.
AU - Jaglowski, Samantha M.
AU - Blum, Kristie
AU - Porcu, Pierluigi
AU - Flynn, Joseph
AU - Penza, Sam
AU - Benson, Don M.
AU - Andritsos, Leslie A.
AU - Devine, Steven M.
N1 - Publisher Copyright:
© 2014 Informa UK, Ltd.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Abstract Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11-cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (> 0.35 μg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy.
AB - Abstract Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11-cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (> 0.35 μg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General improved significantly from cycle 1 to cycle 7, but depression scores from the Center for Epidemiologic Studies Depression scale did not change. Given the toxicities observed, this broad-spectrum deacetylase inhibitor at this schedule is not optimal for prolonged maintenance therapy.
KW - Chemotherapeutic approaches
KW - Lymphoma and Hodgkin disease
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=84929104919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929104919&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.963073
DO - 10.3109/10428194.2014.963073
M3 - Article
C2 - 25213183
AN - SCOPUS:84929104919
SN - 1042-8194
VL - 56
SP - 1043
EP - 1049
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -